PT  - JOURNAL ARTICLE
AU  - Yong, J.H.E.
AU  - Nadeau, C.
AU  - Flanagan, W.
AU  - Coldman, A.
AU  - Asakawa, K.
AU  - Garner, R.
AU  - Fitzgerald, N.
AU  - Yaffe, M.
AU  - Miller, A.B.
AU  - ,
TI  - The OncoSim-Breast cancer microsimulation model
AID  - 10.1101/2020.05.22.20110569
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.22.20110569
4099  - http://medrxiv.org/content/early/2020/05/24/2020.05.22.20110569.short
4100  - http://medrxiv.org/content/early/2020/05/24/2020.05.22.20110569.full
AB  - Background The increasing demand for health care resources requires measures to evaluate the impact of cancer control approaches. A cancer simulation model can help integrate new knowledge to inform clinical and policy decisions. OncoSim-Breast is a breast cancer simulation model. This paper aims to describe the key assumptions in the OncoSim-Breast model and how well it reproduces more recent breast cancer trends and the observed effects in a randomized screening trial.Methods The OncoSim-Breast model simulates the onset, growth and spread of invasive and ductal carcinoma in situ tumours. The model combines Canadian cancer incidence, mortality, screening program and cost data to project population-level outcomes. Users can change the model input to answer specific policy questions. Here we report three validation exercises. First, we compared the model’s projected breast cancer incidence and stage distributions with the observed data in the Canadian Cancer Registry. Second, we compared OncoSim’s projected breast cancer mortality with the Vital Statistics. Third, we replicated the UK Age trial to compare the model’s projections with the trial’s observed screening effects.Results OncoSim-Breast’s projected incidence, mortality and stage distribution of breast cancer were close to the observed data in the Canadian Cancer Registry and the Vital Statistics. OncoSim-Breast also reproduced the breast cancer screening effects observed in the UK Age trial.Interpretation OncoSim-Breast’s ability to reproduce the observed population-level breast cancer trends and the screening effects in a randomized trial increases the confidence of using its results to inform policy decisions related to early detection of breast cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Canadian Partnership Against Cancer, which was funded by Health Canada.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a mathematical modelling study that was conducted using aggregate secondary data; therefore, research ethics approval is not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis paper describes a mathematical model that is available to public sector use at no charge. All model inputs are available in the model to authorized users. http://www.oncosim.ca